Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Immuron Limited ( (AU:IMC) ).
Immuron has announced that CEO Steven Lydeamore will present virtually at the Coffee Microcaps Conference on 5 March 2026, offering investors and industry participants an update on the company’s activities and product portfolio. The event highlights Immuron’s efforts to raise its profile in the microcap investment community as it advances its antibody-based treatments for infectious and gastrointestinal diseases, potentially strengthening engagement with stakeholders and supporting future commercial and development initiatives.
The most recent analyst rating on (AU:IMC) stock is a Sell with a A$0.03 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
More about Immuron Limited
Immuron Limited is an Australian biopharmaceutical company specializing in orally delivered, targeted polyclonal antibodies for infectious diseases, leveraging hyper-immune bovine colostrum as its core platform technology. Its lead commercial product, Travelan, is marketed in Australia, Canada and the U.S. for reducing the risk of travellers’ diarrhea, while the company also develops IMM-529 for recurrent C. difficile infection and distributes ProIBS for irritable bowel syndrome in Australia and New Zealand.
Average Trading Volume: 881,243
Technical Sentiment Signal: Sell
Current Market Cap: A$9.15M
For a thorough assessment of IMC stock, go to TipRanks’ Stock Analysis page.